Related content

Where to for pelvic organ prolapse treatment after the FDA pronouncements? Reply to Pelikan

By Geelen J.   Dwyer P.  

International Urogynecology Journal, Vol. 24, Iss. 11, 2013-11 ,pp. : 1991-1991

Springer Publishing Company

Access to resources Recommend Favorite

Where to for pelvic organ prolapse treatment after the FDA pronouncements?: A systematic review of the recent literature

By Geelen J.   Dwyer P.  

International Urogynecology Journal, Vol. 24, Iss. 5, 2013-05 ,pp. : 707-718

Springer Publishing Company

Access to resources Recommend Favorite

Genetics of pelvic organ prolapse: comment

By Dietz Hans  

International Urogynecology Journal, Vol. 23, Iss. 4, 2012-04 ,pp. : 509-510

Springer Publishing Company

Access to resources Recommend Favorite

Predictors of improved overactive bladder symptoms after transvaginal mesh repair for the treatment of pelvic organ prolapse: Predictors of Improved OAB after POP Repair

By Long Cheng-Yu   Hsu Chun-Shuo   Wu Ming-Ping   Liu Cheng-Min   Chiang Po-Hui   Juan Yung-Shun   Tsai Eing-Mei  

International Urogynecology Journal, Vol. 22, Iss. 5, 2011-05 ,pp. : 535-542

Springer Publishing Company

Access to resources Recommend Favorite

Predictive factors for overactive bladder symptoms after pelvic organ prolapse surgery

By Boer Tiny   Kluivers Kirsten   Withagen Mariella   Milani Alfredo   Vierhout Mark  

International Urogynecology Journal, Vol. 21, Iss. 9, 2010-09 ,pp. : 1143-1149

Springer Publishing Company

Access to resources Recommend Favorite